1
Biopsy
Uses tissue from the biopsy that diagnosed the cancer.
AI and genomics for accessible cancer prognosis
PREDICTIVE GENOMIC INTELLIGENCE
What we do
At PreGen, we use artificial intelligence to find biomarkers that predict tumor aggressiveness and response to treatment.
Why does prognosis matter?
When cancer is diagnosed, it is essential to understand the tumor’s biology to find the right treatment for each patient. That answer determines the choice between active surveillance and treatments with significant side effects.
Why PreGen?
The genomic tests that guide these decisions today cost thousands of dollars and are processed in centralized laboratories. PreGen develops gene signatures that can be measured with standard PCR, in local laboratories, so that precision prognosis is faster and accessible.
Shorter time to results
Processed in local laboratories, with no shipping abroad.
Lower costs
Uses PCR equipment already available in the region’s laboratories.
The sample stays in the country
Tissue is analyzed in the country where the biopsy was taken.
Better clinical decisions
Helps choose between active surveillance and treatment.
How it works
From biopsy to clinical decision
2
RT-qPCR
A local laboratory measures the expression of the signature.
3
AI analysis
Our model turns gene expression into a risk score.
REPORT
LowIntermediateHigh
4
Result
Low, intermediate or high risk, in a clear report for the physician.
5
Clinical decision
Active surveillance or treatment.
Our product
PreGen Prostate
PreGen Prostate is a prognostic test that measures a 10-gene signature by RT-qPCR on the diagnostic biopsy to estimate the tumor’s risk of progression.
In clinical validation · Argentina1.4M+men are diagnosed with prostate cancer every year worldwide.
500,000prostate biopsies per year in Latin America.
USD 3,400+is the cost of a genomic test today, and results can take months.
Platform
One platform, multiple tumors
The same AI platform is being applied to other tumors and biomarkers.
Prostate
Aggressiveness prognosis
Clinical validation
Lung
Response to immunotherapy
Computational development
Melanoma
Response to immunotherapy
Exploratory
News
PreGen among the startups invited to the Deep Tech Summit 2026 Investment Lab
BA Ferial (formerly Costa Salguero), Buenos Aires · 2 p.m.
View post
PreGen pitches at AmCham’s HealthTech day at the Buenos Aires Innovation Park
Pitch at the Biotech & Agrifood Afternoon in Rosario, with GRIDX, Michroma and We are Palta
Meeting with U.S. Ambassador Peter Lamelas and Argentine founders at Palacio Bosch
Pitch at The Engine (MIT) during GRIDX’s U.S. roadshow
Investors
Backed by:
Contact
Let’s talk
Want to join the early access program, invest or collaborate? Write to us and we’ll get back to you shortly.